These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28238899)

  • 1. Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.
    Kudo T; Goda H; Yokosuka Y; Tanaka R; Komatsu S; Ito K
    J Pharm Sci; 2017 Sep; 106(9):2847-2852. PubMed ID: 28238899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
    Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
    Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
    Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes.
    Kudo T; Ozaki Y; Kusano T; Hotta E; Oya Y; Komatsu S; Goda H; Ito K
    Xenobiotica; 2016; 46(3):241-6. PubMed ID: 26290405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.
    Säll C; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Jul; 40(7):1279-89. PubMed ID: 22451699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
    Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
    Kim SJ; Toshimoto K; Yao Y; Yoshikado T; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2715-2726. PubMed ID: 28479356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide.
    Doki K; Darwich AS; Achour B; Tornio A; Backman JT; Rostami-Hodjegan A
    Br J Clin Pharmacol; 2018 May; 84(5):972-986. PubMed ID: 29381228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
    Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
    Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2011 Sep; 39(9):1546-54. PubMed ID: 21697463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
    Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
    Wang JS; DeVane CL
    Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
    Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
    Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications.
    Heinig R; Gerisch M; Bairlein M; Nagelschmitz J; Loewen S
    Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):433-444. PubMed ID: 32125665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats.
    Xu Y; Zhou D; Wang Y; Li J; Wang M; Lu J; Zhang H
    Food Chem Toxicol; 2016 Aug; 94():138-47. PubMed ID: 27259818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
    Wang Y; Wang M; Qi H; Pan P; Hou T; Li J; He G; Zhang H
    Drug Metab Dispos; 2014 Apr; 42(4):782-95. PubMed ID: 24476576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations.
    Filppula AM; Laitila J; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2011 May; 39(5):904-11. PubMed ID: 21289076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of inhibition of CYP2C8 by saroglitazar magnesium: In vivo assessment using montelukast, rosiglitazone, pioglitazone, repaglinide and paclitaxel as victim drugs in Wistar rats.
    Giri P; Delvadia P; Ladani MK; Prajapati N; Gupta L; Patel N; Joshi V; Giri S; Jain MR; Srinivas NR; Patel PR
    Eur J Pharm Sci; 2019 Mar; 130():107-113. PubMed ID: 30633968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.